Adaptimmune says afami-cel BLA accepted for FDA priority review

In a regulatory filing released after the market close on January 31, Adaptimmune disclosed that the FDA has accepted for priority review the company’s Biologics License Application, or BLA, for afami-cel, an investigational engineered T-cell therapy for advanced synovial sarcoma. The application has a Prescription Drug User Fee Act, or PDUFA, target action date of August 4.